Keyphrases
Chronic Lymphocytic Leukemia
100%
Polymorphism
100%
Meta-analysis
100%
Data-centric
100%
Disease Pattern
100%
Murine Double Minute 2 (MDM2)
100%
Individual Patient Data
100%
Single nucleotide Polymorphism
75%
Genotype
50%
Immunoglobulin Heavy Chain Gene
50%
Genetic Analysis
25%
Disease Susceptibility
25%
Overall Survival
25%
Promoter Region
25%
Fluorescence in Situ Hybridization
25%
Small Sample Size
25%
Genetic Risk
25%
Patient Data
25%
Log-rank Test
25%
P53 Pathway
25%
Multivariable
25%
Selection Bias
25%
Mutation Status
25%
Advanced Age
25%
Male Sex
25%
Disease Prognosis
25%
Median Overall Survival
25%
Prognostic Factor Analysis
25%
GC Genotype
25%
Cox Proportional Hazards Regression Analysis
25%
Medicine and Dentistry
B-Cell Chronic Lymphocytic Leukemia
100%
Promoter Region
100%
Meta-Analysis
100%
Patient-Data
100%
Diseases
100%
Single Nucleotide Polymorphism
75%
Overall Survival
50%
Immunoglobulin Heavy Chain
50%
Protein P53
25%
Disease Predisposition
25%
Proportional Hazards Model
25%
Prognostic Factor
25%
Cohort Analysis
25%
Log Rank Test
25%
Factor Analysis
25%
Selection Bias
25%
Genetic Analysis
25%
Genetic Risk Factor
25%
Fluorescence in Situ Hybridization
25%
Biochemistry, Genetics and Molecular Biology
Promoter Region
100%
Patient Coding
100%
Genotyping
75%
Single-Nucleotide Polymorphism
75%
Heavy Chain
50%
Intravenous Immunoglobulin
50%
Overall Survival
50%
Genetics
25%
P53
25%
Fluorescence in Situ Hybridization
25%
Genetic Risk
25%
Sample Size
25%
Factor Analysis
25%
Cohort Study
25%
Immunology and Microbiology
Promoter Region
100%
Patient Coding
100%
Single Nucleotide Polymorphism
75%
Overall Survival
50%
Immunoglobulin Heavy Chain
50%
Fluorescence in Situ Hybridization
25%
P53
25%
Sample Size
25%
Genetic Risk
25%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Lymphatic Leukemia
100%
Diseases
100%
Overall Survival
50%
Immunoglobulin Heavy Chain
50%
Cohort Study
25%
Protein P53
25%
Disease Predisposition
25%
Genetic Risk
25%
Neuroscience
Promoter Region
100%
Meta-Analysis
100%
Single-Nucleotide Polymorphism
75%
Immunoglobulin Heavy Chain
50%
P53
25%
In Situ Hybridization
25%